Some innovative research at Brock University is getting a funding boost.
Brock researchers that have developed a new immunotherapy approach are one step closer to commercializing their treatment for age-related lung disease thanks to a $2.3-million boost from the Canadian Institutes of Health Research.
Working alongside Niagara Health and Ontario Health, the funding will help treat pulmonary fibrosis, a disease with no known cause.
Professor of Health Sciences Newman Sze has already filed a patent for the breakthrough new drug called isoDGR-mAb, an antibody he and his team designed that clears out accumulated proteins damaged by inactive lifestyles, unhealthy diets, environmental stressors and genetic factors.
These harmful proteins, known as isoDGR, break down the normal function of healthy tissue and trigger chronic inflammation, which is associated with conditions such as cardiovascular disease, cancer, Type 2 diabetes, arthritis and Alzheimer’s disease.
Symptoms of the disease include lung scarring and difficulty breathing.
(Written by: Matt Latour)